Loading
ADG126 is an experimental monoclonal antibody from Adagene in phase 2 trials for hepatocellular carcinoma, aimed at CTLA-4.
ADG126 is a monoclonal antibody developed by Adagene and Sanofi. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4. ClinicalTrials.gov describes the intervention as: ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hepatocellular carcinoma. The largest, NCT05584670, plans to enrol 542 participants with primary completion expected 2027-01-19. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4. Connects to CTLA-4.
1.ADG126 binds CTLA-4.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ADG126" OR ABSTRACT:"ADG126") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADG126, not a curated reading list.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares CTLA-4, Hepatocellular carcinoma and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.